The stock ended the session up by over 2%, benefiting from Berenberg's positive analysis. The research firm announced on Friday that it had upgraded bioMérieux from 114.5 to 122.2 euros, while renewing its buy recommendation on the stock.

In a research note, the German financial intermediary considers that the recent correction suffered by the share is unjustified, creating an attractive entry point for the stock.

In the analyst's view, the diagnostics specialist has a solid medium-term outlook, as demonstrated by the well-received investor day on April 9, and the management team has made clear the path it intends to take to achieve its objectives.

Copyright (c) 2024 CercleFinance.com. All rights reserved.